Nomura Holdings’s Passage Bio PASG Stock Holding History

Nomura Holdings’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,869	Closed	-$364K	–	2301
2021 Q4	$364K	Buy	+2,869	New	+$469K	﹤0.01%	1624

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Nomura Holdings's PASG Position: Q1 2022 in Review

Nomura Holdings sold out of Passage Bio (PASG) in Q1 2022, closing a stake of 2,869 shares — an estimated $364K sold.

Nomura Holdings first reported a position in PASG in Q4 2021 and held it in 1 quarter. The position peaked at $364K in Q4 2021. 108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

Nomura Holdings reported no remaining Passage Bio position as of Q1 2022 after selling out during the quarter.
Nomura Holdings sold 2,869 Passage Bio shares in Q1 2022, an estimated $364K.
Nomura Holdings first reported a position in Passage Bio in Q4 2021 and held it in 1 quarter.
Nomura Holdings's Passage Bio position peaked at $364K in Q4 2021.
108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on Nomura Holdings's 13F filing for Q1 2022, filed 18 May 2022.